Export

ATC codes: A07AA06
EMLc
Indication
Visceral leishmaniasis ICD11 code: 1F54.0
INN
Paromomycin
Medicine type
Chemical agent
List type
Core
Formulations
Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
EML status history
First added in 2007 (TRS 946)
Changed in 2007 (TRS 950)
Sex
All
Age
Also recommended for children
Therapeutic equivalence
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
DrugBank
Summary of evidence and Expert Committee recommendations
Paromomycin was considered at the 15th Expert Committee meeting in March 2007, where paromomycin solution for intramuscular (IM) injection was added to the Model List. The Expert Committee concluded that paramomycin was effective in terms of effect on standard endpoints, such as initial and final cure, for the treatment of visceral leishmaniasis in children and adults. Paromomycin is licensed in India, and was granted orphan drug designation by the US Food and Drug Administration (FDA) in March 2005 and the European Medicines Agency (EMEA) in April 2005. The EMLc Subcommittee endorsed the listing of paromomycin IM injection on the first EMLc.